Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133259 | 0.82 | CYP3A4 (0.46) | POLBALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL14895927 | 0.77 | PDPK1 (0.40) | POLBALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL5133459 | 0.77 | SCN2A (0.50) | POLBALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL11006460 | 0.74 | MAPT (0.44) | POLBALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL14896334 | 0.74 | HTT (0.35) | POLBALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL14908385 | 0.74 | GABRP (0.36) | POLBALDH1A1KDM4EGAAHTT | |
| SCHEMBL5202901 | 0.74 | COMT (0.58) | ALDH1A1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL16432053 | 0.73 | LMNA (0.42) | HTTMEN1LMNAKMT2AMAOA | |
| SCHEMBL7560710 | 0.72 | HRH4 (0.58) | HRH4HTR2C | |
| SCHEMBL23860829 | 0.72 | MEN1 (0.45) | POLBALDH1A1SMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1389103-A4 | SYNTHESIS AND EVALUATION OF NOVEL PHTHALIMIDE MIMICS AS ANTI-ANGIOGENIC AGENTS | UNIV VIRGINIA (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040122030-A1 | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2004-06-24 | — | — | US | disclosed |
| EP-1389103-A2 | SYNTHESIS AND EVALUATION OF NOVEL PHTHALIMIDE MIMICS AS ANTI-ANGIOGENIC AGENTS | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002086078-A2 | SYNTHESIS AND EVALUATION OF NOVEL PHTHALIMIDE MIMICS AS ANTI-ANGIOGENIC AGENTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122030-A1 | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic | KDR, FLT4, FLT1 | POLB 3460/4885ALDH1A1 1161/4885SMN1; SMN2 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.